We have evaluated the impact of pretreatment somatic EGFR T@M mutations , TP@ mutations , and Bcl-@ interacting mediator of cell death ( BCL@L@ , also known as BIM ) mRNA expression in @ patients with EGFR-mutant non-small-cell lung cancer ( NSCLC ) included in the EURTAC trial ( trial registration : NCT@ ) .